ChristineAnnaWhiteMD

PubMed

• 29 citations
  Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
  Leo I Gordon, Thomas E Witzig, Greg A Wiseman, Ian W Flinn, Stewart S Spies, Daniel H Silverman, Christos Emmanuolides, Larry Cripe, Mansoor Saleh, Myron S Czuczman, T...> ;Seminars in Oncology. 2002 Feb 1
• 72 citations
  Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in...
  Jane N. Winter, David J. Inwards, Stewart Spies, Gregory A. Wiseman, David Patton, William D. Erwin, Alfred Rademaker, Bing Bing Weitner, Stephanie F. Williams, Martin...> ;Journal of Clinical Oncology. 2009 Apr 1
• 138 citations
  Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
  Jian Qiao, Hongxun Wang, Timothy Kottke, Christine A. White, Katie Twigger, Rosa Maria Diaz, Jill Thompson, Peter Selby, Johann S. de Bono, Alan Melcher, Hardev Pandha...> ;Clinical Cancer Research. 2008 Jan 1
• 42 citations
  The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
  Peter S. Conti, Christine A. White, Peter C. Pieslor, Arturo Molina, Jacqueline Aussie, P. Foster> ;Journal of Nuclear Medicine. 2005 Nov 1
• 10 citations
  Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
  Christine A. White> ;Journal of Experimental Therapeutics & Oncology. 2004 Dec 1
• 29 citations
  Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell n...
  Russell J. Schilder, Arturo Molina, Nancy L. Bartlett, Thomas E. Witzig, Leo I. Gordon, James L. Murray, Stewart Spies, Hua Wang, Gregory A. Wiseman, Christine A. White> ;Cancer Biotherapy & Radiopharmaceuticals. 2004 Sep 24
• 87 citations
  Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
  Leo I. Gordon, Thomas E. Witzig, Arturo Molina, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Katie Vo, Charles Theuer, Brad Pohlman, Nancy L. Bartlett, G. A...> ;Clinical Lymphoma. 2004 Sep 1
• Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 (90Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL).
  Gordon LI, Molina A, Emmanouilides C, Raubitschek A, Darif M, Schilder RJ, Wiseman GA, White CA, Witzig TE> ;J. Clin. Oncol.. 2004-07-15
• 142 citations
  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study
  Leo I. Gordon, Arturo Molina, Thomas E. Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, G. A. Wiseman, Christine A. White> ;Blood. 2004 Jun 15
• 170 citations
  Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
  William H Rastetter, Arturo Molina, Christine A. White> ;Annual Review of Medicine. 2004 Jan 27
• 3 citations
  Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
  Christine A. White> ;Current Pharmaceutical Biotechnology. 2003 Jul 31
• 211 citations
  Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
  Thomas E. Witzig, C.A. White, Leo I. Gordon, Gregory A. Wiseman, Christos Emmanouilides, James L. Murray, John Lister, Pratik S. Multani> ;Journal of Clinical Oncology. 2003 Apr 1
• 20 citations
  Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
  Gregory A. Wiseman, Bryan R. Leigh, William L. Dunn, Michael G. Stabin, Christine A. White> ;Cancer Biotherapy & Radiopharmaceuticals. 2003 Apr 1
• 169 citations
  Radiation Dosimetry Results and Safety Correlations from 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin’s Lymphoma: Combined Data f...
  Gregory A. Wiseman, Ellen Kornmehl, Bryan R. Leigh, William D. Erwin, Donald A. Podoloff, Stewart Spies, Richard B. Sparks, Michael G. Stabin, Thomas E. Witzig, Christ...> ;Journal of Nuclear Medicine. 2003 Mar 1
• 23 citations
  Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
  Gregory A. Wiseman, Bryan R. Leigh, William D. Erwin, Richard B. Sparks, Donald A. Podoloff, Russell J. Schilder, Nancy L. Bartlett, Stewart Spies, Antonio J. Grillo-L...> ;Cancer Biotherapy & Radiopharmaceuticals. 2003 Apr 1
• 31 citations
  Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
  Bita Esmaeli, James L. Murray, M. Amir Ahmadi, Aresu Naderi, Sanjay K. Singh, Jorge E. Romaguera, C.A. White, Peter McLaughlin> ;Archives of Ophthalmology. 2002 Sep 1
• 465 citations
  Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma
  Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon, Christos Emmanouilides, Myron S. Czuczman, Mansoor N. Saleh, Larry Cripe, Gregory A. Wiseman, Teresa Olejnik, Pratik S. ...> ;Journal of Clinical Oncology. 2002 Aug 1
• 208 citations
  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
  Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor N. Saleh, Rober...> ;Blood. 2002 Jun 15
• 830 citations
  Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-G...
  Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Brad Pohlman, Nancy L. Bartlett, Gregory A. Wiseman, Norm...> ;Journal of Clinical Oncology. 2002 May 15
• 76 citations
  Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
  Gregory A. Wiseman, Bryan Leigh, William D. Erwin, Dominick Lamonica, Ellen Kornmehl, Stewart M. Spies, Daniel H. S. Silverman, Thomas E. Witzig, Richard B. Sparks, Ch...> ;Cancer. 2002 Feb 15
• Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
  Gordon, L. I., Witzig, T. E., Wiseman, G. A., Flinn, I. W., Spies, S. S., Silverman, D. H., Emmanouilides, C., Cripe, L., Saleh, M., Czuczman, M. S., Olejnik, T., Whit...> ;Semin Oncol. 2002 Feb
• 22 citations
  Non-Hodgkins Lymphoma: Review of Conventional Treatments
  P. Multani, Christine A. White, Antonio J. Grillo-Lopez> ;Current Pharmaceutical Biotechnology. 2001 Nov 30
• 16 citations
  Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.
  Antonio J. Grillo-Lopez, B. K. Dallaire, A. McClure, R. Weaver, C. Varns, A. Wei, R. Allen, D. Lee, D. Shen, J. E. Leonard, P. Multani, Christine A. White> ;Current Pharmaceutical Biotechnology. 2001 Nov 30
• 23 citations
  Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing.
  Gerald L. DeNardo, Malik E. Juweid, Christine A. White, Gregory A. Wiseman, Sally J. DeNardo> ;Critical Reviews in Oncology/hematology. 2001 Aug 1
• 133 citations
  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transforme...
  Gregory A. Wiseman, Christine A. White, Richard B. Sparks, William D. Erwin, Donald A. Podoloff, Dominick Lamonica, Nancy L. Bartlett, J. Anthony Parker, William L. Du...> ;Critical Reviews in Oncology/hematology. 2001 Aug 1
• Join now to see all